1. A new niclosamide derivatives-B17 can inhibit urological cancers growth through apoptosis-related pathway
   Chia-Lun Wu et al, 2018, Cancer Med CrossRef
2. Conjugation of Ginsenoside with Dietary Amino Acids: A Promising Strategy To Suppress Cell Proliferation and Induce Apoptosis in Activated Hepatic Stellate Cells
   Lu Ma et al, 2019, J. Agric. Food Chem. CrossRef
3. Research Advances in the Use of Histone Deacetylase Inhibitors for Epigenetic Targeting of Cancer.
   Yu Bai et al, 2019, Curr Top Med Chem CrossRef
4. Current overview on the clinical update of Bcl-2 anti-apoptotic inhibitors for cancer therapy
   Vasanti Suvarna et al, 2019, European Journal of Pharmacology CrossRef
5. Calreticulin regulated intrinsic apoptosis through mitochondria-dependent and independent pathways mediated by ER stress in arsenite exposed HT-22 cells
   Xiaotong Wang et al, 2020, Chemosphere CrossRef
6. Bcl-2/Bcl-xl inhibitor APG-1252-M1 is a promising therapeutic strategy for gastric carcinoma.
   Hanjie Yi et al, 2020, Cancer Med CrossRef
7. Inhibition of Anti-Apoptotic Bcl-2 Proteins in Preclinical and Clinical Studies: Current Overview in Cancer.
   Simona D'Aguanno et al, 2020, Cells CrossRef
8. Anticancer Agents Based on Vulnerable Components in a Signalling Pathway
   Ankur Vaidya et al, 2020, MRMC CrossRef
9. Rational design, synthesis and biological evaluation of triphenylphosphonium-ginsenoside conjugates as mitochondria-targeting anti-cancer agents
   Lu Ma et al, 2020, Bioorganic Chemistry CrossRef
10. The interplay between apoptosis and cellular senescence: Bcl-2 family proteins as targets for cancer therapy.
    Alakananda Basu, 2022, Pharmacol Ther CrossRef
11. Gemcitabine and APG-1252, a novel small molecule inhibitor of BCL-2/BCL-XL, display a synergistic antitumor effect in nasopharyngeal carcinoma through the JAK-2/STAT3/MCL-1 signaling pathway
    Fan Luo et al, 2021, Cell Death Dis CrossRef
12. Strategies to Reduce the On‐Target Platelet Toxicity of Bcl‐x L Inhibitors: PROTACs, SNIPERs and Prodrug‐Based Approaches
    Arvind Negi et al, 2022, ChemBioChem CrossRef
13. Mcl-1 levels critically impact the sensitivities of human colorectal cancer cells to APG-1252-M1, a novel Bcl-2/Bcl-XL dual inhibitor that induces Bax-dependent apoptosis
    Weilong Yao et al, 2022, Neoplasia CrossRef
14. Therapeutic potential of the novel Bcl‐2/Bcl‐X L dual inhibitor, APG1252, alone or in combination against non‐small cell lung cancer
    Luxi Qian et al, 2022, Molecular Carcinogenesis CrossRef
15. Anti-tumor effect of antibody drug conjugate ASP1235 targeting Fms-like tyrosine kinase 3 with venetoclax plus azacitidine in an acute myeloid leukemia xenograft mouse model
    Hirofumi Tsuzuki et al, 2022, Oncotarget CrossRef
16. Programmed cell death, redox imbalance, and cancer therapeutics.
    Xiaofeng Dai et al, 2021, Apoptosis CrossRef
17. Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
    Xin Xie et al, 2023, Sig Transduct Target Ther CrossRef
18. B‐cell lymphoma‐2 family proteins in the crosshairs: Small molecule inhibitors and activators for cancer therapy
    Qineng Gong et al, 2023, Medicinal Research Reviews CrossRef
19. BCL-2 inhibition in haematological malignancies: Clinical application and complications
    Dominic J. Fowler-Shorten et al, 2024, Blood Reviews CrossRef
20. Brucine Inhibits Proliferation of Pancreatic Ductal Adenocarcinoma through PI3K/AKT Pathway-induced Mitochondrial Apoptosis
    You Wu et al, 2024, CCDT CrossRef
21. APG-1252 combined with Cabozantinib inhibits hepatocellular carcinoma by suppressing MEK/ERK and CREB/Bcl-xl pathways
    Tian Di et al, 2024, International Immunopharmacology CrossRef
22. The novel BCL-2/BCL-XL inhibitor APG-1252-mediated cleavage of GSDME enhances the antitumor efficacy of HER2-targeted therapy in HER2-positive gastric cancer
    Qiu-yun Luo et al, 2024, Acta Pharmacol Sin CrossRef